Swiss National Bank Has $387.94 Million Stake in Pfizer Inc. $PFE

Swiss National Bank reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,580,012 shares of the biopharmaceutical company’s stock after selling 808,500 shares during the period. Swiss National Bank’s holdings in Pfizer were worth $387,942,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Principal Securities Inc. raised its holdings in Pfizer by 8.2% during the fourth quarter. Principal Securities Inc. now owns 124,862 shares of the biopharmaceutical company’s stock valued at $3,109,000 after buying an additional 9,516 shares in the last quarter. Great Lakes Advisors LLC raised its holdings in Pfizer by 1,116.8% during the fourth quarter. Great Lakes Advisors LLC now owns 520,283 shares of the biopharmaceutical company’s stock valued at $12,955,000 after buying an additional 477,525 shares in the last quarter. Aviva PLC raised its holdings in Pfizer by 5.6% during the fourth quarter. Aviva PLC now owns 4,711,266 shares of the biopharmaceutical company’s stock valued at $117,311,000 after buying an additional 250,486 shares in the last quarter. Resurgent Financial Advisors LLC raised its holdings in Pfizer by 10.3% during the fourth quarter. Resurgent Financial Advisors LLC now owns 37,715 shares of the biopharmaceutical company’s stock valued at $939,000 after buying an additional 3,513 shares in the last quarter. Finally, Investment Research Partners LLC raised its holdings in Pfizer by 15.9% during the fourth quarter. Investment Research Partners LLC now owns 15,857 shares of the biopharmaceutical company’s stock valued at $395,000 after buying an additional 2,174 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a report on Tuesday. Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th. BMO Capital Markets restated an “outperform” rating and set a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a report on Monday, March 2nd. Finally, Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $28.82.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded HYMPAVZI’s U.S. indication to include more hemophilia A and B patients, including pediatric use, improving Pfizer’s rare-disease growth outlook and potentially boosting future sales. Pfizer shares climb 3.2% as investors digest expanded U.S. label for HYMPAVZI
• Positive Sentiment: RBC Capital Markets upgraded Pfizer to Sector Perform, saying the stock’s recent weakness has improved the risk-reward profile and reset valuation ahead of key pipeline catalysts. Pfizer upgraded by RBC as valuation resets ahead of key pipeline catalysts
• Positive Sentiment: Multiple articles highlighted Pfizer’s obesity, oncology, and pneumococcal pipeline updates, signaling continued investment in new growth drivers beyond COVID-era revenues. Pfizer’s New Phase 1 PF-07799544 Study Adds Quiet Depth to Its R&D Pipeline
• Neutral Sentiment: Articles discussing Pfizer’s dividend yield and whether the stock is a buy or hold are mostly commentary, but they reinforce investor interest in PFE as an income name. A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25
• Negative Sentiment: Pfizer’s CEO warned that planned investment in Germany could be reconsidered because of proposed drug-pricing changes, underscoring ongoing policy risk for the company. Pfizer CEO warns German investment at risk over drug pricing policies

Pfizer Trading Up 2.2%

Shares of NYSE:PFE opened at $26.17 on Friday. The company has a market cap of $149.15 billion, a P/E ratio of 19.98 and a beta of 0.34. The stock’s 50-day moving average is $26.48 and its 200-day moving average is $26.32. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue was up 5.4% compared to the same quarter last year. During the same period last year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.